| Characteristics | Baseline Assessment |
| Age, years | 59 [56 - 61] |
| Gender |
|
| Male | 2 |
| Female | 9 |
| Anti-hypertensive treatment |
|
| Diuretics | 6 |
| Angiotensin Converting Enzyme inhibitors (ACEIs) | 3 |
| Angiotensin II Receptor Blockers (ARA-II) | 2 |
| Calcium channel blockers | 8 |
| Beta blockers | 6 |
| Monotherapy | 3 |
| Bitherapy | 4 |
| Triple therapy and/or more | 4 |
| Anthropometric characteristics |
|
| Weight (kg) | 78.7 [71.6 - 85.1] |
| BMI (kg/m2) | 29.5 [25.1 - 31.5] |
| Fat mass (g) | 37.1 [33.0 - 41.5] |
| Abdominal circumference (cm) | 96.0 [93.0 - 105.0] |
| SBP (mmHg) | 133 [112 - 147] |
| DBP (mmHg) | 87 [71 - 93] |
| Biological characteristics |
|
| Fasting blood glucose (mg/dl) | 84 [76 - 95] |
| Glycated hemoglobin (HbA1c, %) | 4.9 [4.6 - 5.5] |
| ALAT (IU/mL) | 17 [8.6 - 32.1] |
| Total-Cholesterol (mg/dl) | 190 [160 - 210] |
| LDL-Cholesterol (mg/dl) | 120 [80 - 140] |
| HDL-Cholesterol (mg/dl) | 40 [40 - 50] |
| Triglyceride (mg/dl) | 150 [90 - 190] |
| eGFR, MDRD (mL/min/1.73m2) | 66.0 [58.5 - 91.5] |